diphenyl-1-pyrenylphosphine has been researched along with ascorbic acid in 1 studies
| Studies (diphenyl-1-pyrenylphosphine) | Trials (diphenyl-1-pyrenylphosphine) | Recent Studies (post-2010) (diphenyl-1-pyrenylphosphine) | Studies (ascorbic acid) | Trials (ascorbic acid) | Recent Studies (post-2010) (ascorbic acid) |
|---|---|---|---|---|---|
| 22 | 1 | 7 | 45,261 | 2,497 | 11,176 |
| Protein | Taxonomy | diphenyl-1-pyrenylphosphine (IC50) | ascorbic acid (IC50) |
|---|---|---|---|
| Chain A, Hyaluronidase, phage associated | Streptococcus pyogenes | 1000 | |
| Urease | Canavalia ensiformis (jack bean) | 8.59 | |
| Solute carrier family 23 member 1 | Homo sapiens (human) | 156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujitani, Y; Hirose, T; Kanazawa, A; Kawamori, R; Ohmura, C; Sakai, K; Shimizu, T; Uchino, H; Watada, H | 1 |
1 trial(s) available for diphenyl-1-pyrenylphosphine and ascorbic acid
| Article | Year |
|---|---|
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxides; Male; Middle Aged; Organophosphorus Compounds; Pyrenes; Vitamin E | 2007 |